O bservational studies using administrative data require proper comorbidity adjustment to reduce bias. 1 Two popular methods are the Elixhauser comorbidity system, 2 a set of 30 comorbidity indicators, and the Charlson comorbidity index-a composite score summarized by a weighted combination of 17 comorbidities. 3 While interpreting 30 indicators and modeling numerous interactions can be difficult, 4 Elixhauser et al 2 recommended against a single score. Despite several studies demonstrating Elixhauser's comorbidity system to be statistically superior for predicting various outcomes, 5-8 the Charlson comorbidity index continues to be used. [9] [10] [11] A composite score provides an attractive advantage over 30 indicators by reducing overfitting risk in small datasets and limiting computational requirements in large datasets. To avoid these issues, some researchers [12] [13] [14] summarize the number of Elixhauser comorbidities-either as a comorbidity count, or categorized as 0, 1, 2, or Z3 comorbidities-under the questionable 13 assumption that each comorbidity equally affects outcome.
van Walraven et al 4 developed a composite score (VW score) for the Elixhauser comorbidities by modeling inhospital mortality with inpatient admission data (Ottawa Hospital, Ontario, Canada, 1996 . The VW score discriminated in-hospital mortality similarly to using 30 individual comorbidities, 4 as well as long-term cancer survival in a subsequent study involving United States (US) Medicare beneficiaries. 15 Researchers frequently use comorbidity adjustments in administrative datasets including the Nationwide Inpatient Sample (NIS) and State Inpatient Database (SID) from the Healthcare Cost and Utilization Project (HCUP) sponsored by the Agency for Healthcare Research and Quality. 16 The NIS includes all inpatient admissions from a stratified sample of approximately 1000 US hospitals, yielding approximately 8 million records annually. The SID includes US state-specific censes of inpatient discharges. HCUP provides software for converting International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes to Elixhauser comorbidity indicators. Using diagnosis-related group codes, the software disregards ICD-9-CM diagnosis codes related to principal diagnoses to better identify comorbidities.
Beginning in 2004, cardiac arrhythmia (CA) was excluded from the comorbidity software following concerns about its reliability as a comorbidity. 17 Unlike the NIS, the SID contains present-on-admission (POA) indicators accompanying each reported diagnosis, providing greater discriminative ability between comorbidities and hospital-acquired conditions. Thus, one can correctly apply van Walraven's weights for all 30 Elixhauser comorbidities in the SID using POA indicators. However, in the NIS where only 29 comorbidities are included and no POA indicators are available, researchers applying the VW score implicitly assign a CA comorbidity weight of 0, as opposed to the originally assigned 5 (VW weights range from À 7 to 12).
Evidence suggests that the VW score may be sensitive to exclusion of CA in the derivation process. In van Walraven's analysis, CA was significantly correlated with valvular disease and the unadjusted and adjusted odds ratios for valvular disease indicated a positive and negative association with in-hospital mortality, respectively. 4 Because regression models with correlated predictors can produce unstable coefficient estimates, 18 rederiving the VW score without CA could produce different results.
We address the practical concern of applying the VW score in the NIS by deriving new summary scores and assessing their sensitivity to exclusion of CA. To our knowledge, we provide the first assessment of the VW score in a US national sample of hospital discharges.
METHODS

Data Source
We utilized the 2009 Maryland SID to derive new summary scores due to the state's ethnically and geographically diverse population 19 and sufficient sample size. We excluded maternity-related admissions, transfers in and out of the hospital, and same-day surgeries, combined with further reductions to maintain comparability with the VW score sample (n = 228,565). We applied HCUP comorbidity software version 3.5 17 to code the 29 currently available Elixhauser comorbidities; for CA, we used a previous version of the software from the last year CA was included (2004) . Positive evidence for a comorbidity required a positive or exempt POA status accompanying the diagnosis code. For validation, we used 2009 NIS data, employing the same exclusion criteria as with the SID. We included ICD-9-CM diagnosis codes within each record's first 25 and 35 diagnoses for the NIS and SID samples, respectively.
Rederivation of the Summary Score
Replicating the VW score derivation methods, we derived 2 new summary scores-SID 30 and SID 29 -by creating multivariable logistic regression models for in-hospital mortality using the full 30 or 29 (excluding CA) Elixhauser comorbidities, respectively, as predictors. We used backward stepwise elimination, retaining variables with P < 0.05. Dividing regression coefficients by the smallest absolute coefficient, rounded to the nearest integer, produced the comorbidity weights. 20 Nonretained Elixhauser comorbidities received 0-point weights. We summed the assigned weights for each Elixhauser comorbidity to calculate the summary score for each hospitalization. We derived the new scores using SAS, version 9.3 (SAS Institute, Cary, NC).
Comparison of Various Adjustment Techniques
We applied the rederived summary and VW scores to 2009 NIS data. To compare the performance of these composite scores and other comorbidity measures, we created 7 multivariable logistic regression models predicting in-hospital mortality. Our baseline model included predictors used in another assessment 21 of the Elixhauser comorbidities: age, sex, race, length of stay, expected primary payer, and an operation status indicator, defined by the presence of an ICD-9-CM procedure code in either the major diagnostic or therapeutic AHRQ Procedure Classes. 22 Other models were created by adding the following predictors to the baseline model: (1) (6) a categorical variable defined by 0, 1, 2, or Z3 Elixhauser comorbidities (Count 4 ). To account for the stratified sampling scheme present in NIS data, we incorporated discharge sampling weights in all models. 23, 24 To assess the validity of the comorbidity adjustments, we examined several model performance criteria. We compared overall model performance using the scaled Brier score (range, 0%-100%; higher values indicate better performance). 25, 26 Calibration (ie, the agreement between observed outcome incidences and a model's predicted probabilities) was assessed graphically. Discrimination, a measure of each model's ability to distinguish which patients died in hospital, was compared using the concordance (c) statistic. We graphed receiver-operating characteristic curves for visual presentation of the c statistics. Relative to the baseline model, we compared the 6 comorbidity-adjusted models using net reclassification improvement (NRI), [27] [28] [29] [30] which measures the degree of improvement in predicted probabilities of in-hospital mortality when adding a comorbidity adjustment to the baseline model. Higher NRI values indicate better reclassification. We used bootstrap methods to compute 95% confidence intervals for performance measures and to compare c statistics. We used R, version 3.0.0 31 for model comparisons.
RESULTS
Rederivation of Summary Scores
The 2009 Maryland SID contains 773,472 inpatient admissions to 51 community hospitals. Of these, 550,104 admissions from 50 hospitals met inclusion criteria. We randomly selected 228,565 of these admissions for rederivation of the summary score with all 50 hospitals represented. Mean patient age was 59.9 (SD = 18.7) with 45.2% female. The median length of stay was 3 days (interquartile range, 2-5 d) and 26.6% of admissions involved an operation. The in-hospital mortality rate was 2.2%. Table 1 displays the prevalence of each comorbidity across the samples. For most comorbidities, the prevalence was higher in our derivation sample than either van Walraven's or Elixhauser's sample. Table 1 contains the odds ratios and associated weights for each comorbidity and each score. In comparing the VW score to our rederived scores, comorbidities with substantial differences in adjusted odds ratios and corresponding weights included liver disease, lymphoma, and coagulopathy.
Comparison of Models Using NIS Data
More than 98% of admissions had predicted probability of in-hospital mortality between 0.002 and 0.2 for all models. Within this range of predicted probability, all models displayed reasonable calibration; although, the Binary 29 , VW score, SID 30 , and SID 29 models displayed slight miscalibration among patients with predicted probabilities of in-hospital mortality between 0.002 and 0.01 (Fig. 1 ). All models displayed miscalibration above predicted probabilities of 0.2, although less than about 0.9% of admissions (depending on the model) had such high predicted probabilities. 30 , and VW score models had substantially better discriminative ability, with SID 29 and SID 30 slightly outperforming the VW score. Figure 2 depicts receiver-operating characteristic curves for the models. All pairs of c statistics were significantly different (all Bonferroni-adjusted P < 0.0001). Scaled Brier scores demonstrated similar patterns. Compared with the baseline model, the Binary 29 model increased predicted probabilities in 61.3% of patients who died and decreased predicted probabilities in 73.4% of patients discharged alive, resulting in the highest NRI. The composite score models had much higher NRI than the Count and Count 4 models.
DISCUSSION
Using 2009 Maryland SID data, we rederived van Walraven's summary score for the original 30 and reduced set of 29 Elixhauser comorbidities. We examined the performance of various Elixhauser comorbidity adjustment techniques using 2009 NIS data. Several comorbidities had substantially higher prevalence in our population than in either van Walraven's or Elixhauser's population. Although these differences may be real, other reasons for these discrepancies may include changes in coding practices or structural changes in the populations analyzed. Our rederived weights remained fairly similar for 29 versus 30 comorbidities, but differed from van Walraven's weights.
Despite differences in comorbidity prevalence and derived weights, the VW score performed well in the 2009 NIS dataset. Our rederived scores performed only minimally better than the VW score on all performance measures. Models incorporating composite scores performed nearly as well as the Binary 29 model. The Count and Count 4 models had substantially poorer performance on all measures except Unadjusted odds ratios for van Walraven's sample (VW) and our sample (MD 2009). Adjusted odds ratios from final models and associated weights for van Walraven's sample (VW) and our models using all 30 original Elixhauser comorbidities (SID 30 ) and the 29 that excluded cardiac arrhythmia (SID 29 ). calibration. The observed miscalibrations among low-risk patients (< 0.01 predicted probability) for the Binary 29 , VW score, SID 29 , and SID 30 models were minimal. The composite scores developed here or by van Walraven can be readily applied to administrative datasets by summing the assigned weights for each comorbidity present in the record. We include a SAS macro and R function to calculate the various composite scores (see text files, Supplemental Digital Contents 1 and 2, http://links.lww.com/MLR/A901 and http://links. lww.com/MLR/A902). The SID 30 score had minimal but statistically significant better discrimination than the SID 29 or VW scores in the 2009 NIS dataset. Researchers using the NIS data may wish to summarize comorbidity with the SID 30 score; however, it is not clear whether the SID 30 score would have superior performance in other datasets.
Our study has limitations. We modeled in-hospital mortality, whereas others 32, 33 have proposed that 30-day mortality represents a less-biased alternative. We derived our scores using statistical criteria; clinical knowledge is needed to determine each comorbidity's importance. Our summary scores were derived using administrative data and may not be applicable to studies involving primary or prospective data collection. Codes used to determine comorbidity may not accurately portray a patient's true comorbidity status. 4 Some comorbidities were interrelated (range of c statistics for comorbidities regressed on the other 28, excluding CA: 0.61-0.85). Finally, our analysis was based on all inpatient admissions; the validity of composite scores within specific conditions requires further assessment.
Our use of a diverse population including 50 Maryland hospitals in 2009 to derive summary scores represents a strength of our study. Further, we used POA indicators to refine patients' comorbidity status and externally validated ours and van Walraven's summary scores in 2009 NIS data. To our knowledge, this is the first study to validate any Elixhauser summary score in US national inpatient data. Finally, we used multiple measures to provide a robust comparison of model performance.
van Walraven's composite score is valid in the NIS, despite being derived using all 30 original Elixhauser comorbidities instead of the 29 currently available in the NIS. Our rederived scores similarly outperformed van Walraven's score by a small margin, implying that inclusion/exclusion of CA in summary score derivation matters little, even though CA was a strong predictor of in-hospital mortality. Models adjusting for comorbidity using composite scores substantially outperformed models using simple comorbidity counts that may not adequately adjust for comorbidity. Researchers wishing to summarize Elixhauser comorbidities with a single value should utilize van Walraven's score or those derived in this study.
